2019
Mixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance
Tan W, Teo C, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew‐Graves C, Ng C, Kelly J, Khetrapal P, ridhar A, Baker H, Ocampo F, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Dann A, Cook J, Cornwell M, Mills R, Knight H, Maher S, Rane A, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Dawson L, Roberts H, Main C, Jain S, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, inclair A, Storr E, Cogley L, Natale S, Lovegrove W, Smith S, Smith K, Hewitt D, Sriram R, Atkinson K, Royle L, Madine J, MacLean K, Walsh J, Guerdette M, Hill M, Payne D, Power A, Cannon J, Devereaux L, Thompson A, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Wardle H, Wilson D, Bayles A, Pelluri S, Pati J, Gherman A, Scott C, Madaan S, Taylor A, Edmunds E, Moore J, Rees A, Williams S, Caddy S, Dukes S, Goffe A, Buckhorn K, Nichols L, Acher P, Baillie K, Middleton K, Proctor C, Cresswell J, Chilvers A, Cain M, Vaux A, Watson D, Bradfield S, Gregory H, Mostafid H, Kehoe L, Drakeley S, Davies A, Williamson L, Krishnan R, Lunt N, Hill P, Burns H, Townley B, Wilkinson L, Wassall H, Hunt J, Holbrook B, Stancombe L, Morrison J, Vankoutrik L, Misra S, Fossey G, Richards A, Mcdonald K, Henderson A, Fennelly R, Tribbeck M, Ames K, Borwell J, Kotze M, Beesley K, Rennie K, Porter T, Gipson A, Piper L, Bailey L, Chrisopoulou A, Slevin K, McCartin F, Warburton H, Hathaway‐Lees S, Whetton K, Delves G, Day A, Bankole T, Broadhead S, Malde S, Oblak M, Ellis D, Bishara S, Barias‐Lara T, Donkov I, Thatcher H, Morris M, Culmsee C, Menzies H, Bartlett C, Cutting C, O'Brien N, Jannapureddy R, Kelkar A, Fitzgerald J, Longhurst S, Worth C, Peracha M, Mzazi S, Poile C, Griffiths L, Cook A, Barber N, Brar N, lty A, Zelhof B, Blades R. Mixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. BJU International 2019, 124: 408-417. PMID: 30694612, PMCID: PMC6767410, DOI: 10.1111/bju.14690.Peer-Reviewed Original ResearchConceptsMinimally acceptable sensitivityAdverse eventsMixed-methods approachUrine biomarkersUrinary biomarkersProspective multicentre observational studyUrinary biomarker testsUrinary tract symptomsHome to hospitalAssociated with adverse eventsUrinary tract infectionHigh-risk patientsMulticentre observational studySensitivity of cystoscopyBladder cancer surveillanceDiagnosis of cancerSemi-structured interviewsPrevalence of haematuriaPatient experiencePatient perspectivePatients' viewsCancer surveillanceTract infectionsUrine biomarker studiesPatient demographics
2018
Novel urinary biomarkers for the detection of bladder cancer: A systematic review
Tan W, Tan W, Tan M, Khetrapal P, Dong L, deWinter P, Feber A, Kelly J. Novel urinary biomarkers for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews 2018, 69: 39-52. PMID: 29902678, DOI: 10.1016/j.ctrv.2018.05.012.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueUrinary biomarkersBladder cancerReceiver operating characteristicRisk of biasPredictive valueNon-muscle invasive bladder cancer patientsBiomarkers investigated to dateInvasive bladder cancer patientsDetection of bladder cancerDiagnosis of bladder cancerSystematic reviewNovel urinary biomarkersBladder cancer patientsQUADAS-2 toolCase-control studyAssessed risk of biasSpecificity of biomarkersPositive test resultsSystematic searchUrinary cytologySurveillance cystoscopyComprehensive systematic reviewQUADAS-2The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review
Khetrapal P, Lee M, Tan W, Dong L, de Winter P, Feber A, Kelly J. The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews 2018, 66: 56-63. PMID: 29684744, DOI: 10.1016/j.ctrv.2018.03.007.Peer-Reviewed Original ResearchConceptsCirculating tumor cellsBladder cancerBlood-based biomarkersValidation cohortTumor cellsDiagnostic value of circulating tumor cellsCirculating tumor cell biomarkerDetection of bladder cancerSystematic reviewCell-free DNAIndependent validation cohortCirculating nucleic acidsSolid cancersAUC/ROC valueUrinary biomarkersMedian numberDiagnostic valueCancerBiomarker sensitivityBiomarkersNucleic acidsBladderSystematic searchCohortAUC/ROCUrinary biomarker for the detection of recurrence following non- muscle invasive bladder cancer: are we there yet?
Tan W, Tan W. Urinary biomarker for the detection of recurrence following non- muscle invasive bladder cancer: are we there yet? Translational Andrology And Urology 2018, 7: s109-s110. PMID: 29644175, PMCID: PMC5881187, DOI: 10.21037/tau.2017.12.18.Peer-Reviewed Original Research
2017
UroMark—a urinary biomarker assay for the detection of bladder cancer
Feber A, Dhami P, Dong L, de Winter P, Tan W, Martínez-Fernández M, Paul D, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng K, Zeegers M, Bryan R, James N, Paramio J, Freeman A, Beck S, Kelly J. UroMark—a urinary biomarker assay for the detection of bladder cancer. Clinical Epigenetics 2017, 9: 8. PMID: 28163793, PMCID: PMC5282868, DOI: 10.1186/s13148-016-0303-5.Peer-Reviewed Original ResearchConceptsDetection of bladder cancerEpigenetic alterationsSequencing assayNovel high-throughputBladder cancerBackgroundBladder cancerNext-generation sequencing assayUrinary biomarkersDNA methylationMuscle-invasive bladder cancerUrinary biomarker assaysSediment DNAAnalysis pipelineVoided urine samplesDetection of BCPrimary BCHigh-throughputCystoscopic examinationVoided urineDNAIndependent cohortAssayBiomarker panelDiagnosed BCCancer